Month: September 2025

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an upsized underwritten public offering of 9,803,921 shares of its common stock at a public offering price of $25.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,470,588 shares of its common stock....

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):$600 million of 4.450% Notes due 2031 (the “2031 Notes”); $900 million of 5.200% Notes due 2035 (the “2035 Notes”); and $500 million of 5.950% Notes due 2055 (the “2055 Notes”).The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025, subject to the satisfaction of customary closing conditions. Royalty Pharma intends to use the net proceeds from the Notes for general corporate purposes. BofA Securities, Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley and TD Securities are acting...

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the following actions to reinforce its commitment to performance and delivery:Comprehensive Operations Review, launched in August, focused on improving performance with a detailed QB action plan, identifying opportunities to enhance operating practices, and reinforcing confidence that future business plans are both reasonable and achievable. Onboarded industry veteran as Special Advisor to the CEO to help accelerate QB tailings management facility (TMF) development and drive operational performance. Defer sanctioning of major growth projects until QB achieves steady-state operations and ramp-up targets.The Comprehensive Operations Review, launched in August, includes detailed assessments...

CALGARY, ALBERTA, Sept. 02, 2025 (GLOBE NEWSWIRE) — Marksmen Energy Inc. (the “Corporation” or “Marksmen”) (TSXV: MAH) announces that further to its news release dated April 30, 2025, the letter of intent with T1 Technology Corporation, has been terminated by Marksmen as the parties were unable to enter into a definitive agreement by the deadline.Marksmen is an active Exploration and Production, oil and gas company, concentrating in the Appalachian Basin, USA. In Ohio, a joint interest partner is currently drilling a well, at 100% their cost, and is nearing total depth.  The well is on a property targeted by Marksmen 3D seismic.  Pursuant to an agreement, Marksmen will earn a 6% gross overriding royalty, after payout.   Also in Ohio, another joint venture partner has acquired a portion of one of the Corporation’s leases...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. LEQEMBI is indicated for the treatment...

Not for distribution to U.S. news wire services or dissemination in the United States. This news release constitutes a “designated news release” for the purposes of the Corporation’s prospectus supplement dated December 9, 2024 to Fortis’ short form base shelf prospectus dated December 9, 2024. ST. JOHN’S, Newfoundland and Labrador, Sept. 02, 2025 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX: FTS) announced today that it has priced an offering by private placement (the “Offering”), pursuant to the exemptions from the prospectus requirements of applicable Canadian securities laws, of $750 million aggregate principal amount of 5.100% fixed-to-fixed rate subordinated notes due December 4, 2055 (the “Notes”). The Offering is being made...

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced that it plans to release its fourth quarter and fiscal year-end 2025 financial and operating results on Tuesday, September 16, 2025, after the market closes. Additionally, Kelly Loyd, President and Chief Executive Officer, Ryan Stash, Senior Vice President, Chief Financial Officer, and Treasurer, and Mark Bunch, Chief Operating Officer, will review the results on a conference call at 10:00 a.m. Central Time on Wednesday, September 17, 2025. Conference Call and Webcast Details Date: Wednesday, September 17, 2025Time: 10:00 a.m. Central TimeDial-In: (844) 481-2813International Dial-In: (412) 317-0677Note: Dial-in participants should ask to join the Evolution Petroleum...

New York, Sept. 02, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC), (“BNC” or “the Company”), a growth-oriented company focused on managing the world’s largest corporate treasury of BNB, today announced the appointment of Dr. Russell Read, Ph.D., CFA, as a Non-Executive Director of the Company, effective immediately. Dr. Read brings more than three decades of global investment leadership and governance experience across sovereign wealth funds, pension systems, private investment firms, and financial institutions in North America, Europe, Asia, and the Middle East. Currently, Dr. Read serves as Co-Founder, Chief Investment Officer, and Director at Measa Partners, a global investment and advisory firm. He previously held senior leadership roles as Chief Investment Officer of the California Public Employees Retirement System...

SAN JOSE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — To help encourage its customers to save more water, California Water Service (Cal Water) has increased the value of conservation rebates available for purchases of popular indoor and outdoor conservation-related products. For a limited time, customers can get increased rebates on a range of products, from high-efficiency clothes washers to low-water-use landscaping. Rebates with increased incentives include:Residential high-efficiency toilets, now up to $150 Residential high-efficiency clothes washers, now up to $500 Residential lawn-to-garden conversions, now up to $5 per square foot Commercial high-efficiency toilets, now up to $200 Commercial high-efficiency urinals, now up to $300 Commercial lawn-to-garden conversions, now up to $3 per square footRebate funds are limited...